维得利珠单抗治疗炎症性肠病的真实世界临床、内镜和影像学疗效
这项回顾性队列研究纳入2012至2017年接受维得利珠单抗治疗的222例成人炎症性肠病患者(122例克罗恩病、100例溃疡性结肠炎),评估诱导后3、6、12个月的临床和客观缓解率。克罗恩病临床缓解率分别为19.8%、22.1%、22.1%,溃疡性结肠炎分别为51.0%、61.8%、61.9%。多变量分析显示溃疡性结肠炎和病情较轻者更可能获得客观缓解。
要点
- 维得利珠单抗在克罗恩病和溃疡性结肠炎中均对诱导和维持临床及客观缓解有效。
- 溃疡性结肠炎临床缓解率在3、6、12个月分别为51.0%、61.8%、61.9%。
- 克罗恩病临床缓解率在3、6、12个月分别为19.8%、22.1%、22.1%。
核心结论
- 维得利珠单抗在克罗恩病和溃疡性结肠炎中均对诱导和维持临床及客观缓解有效。
研究设计与样本
- 回顾性队列研究,纳入2012至2017年接受维得利珠单抗治疗的成人克罗恩病和溃疡性结肠炎患者,共222例(122例克罗恩病,100例溃疡性结肠炎)。
主要发现
- 克罗恩病临床缓解在3、6、12个月分别为19.8%(22/111)、22.1%(21/95)、22.1%(15/68)。
- 克罗恩病客观缓解在3、6、12个月分别为11.5%(6/52)、21.2%(14/66)、18.9%(7/37)。
- 溃疡性结肠炎临床缓解在3、6、12个月分别为51.0%(51/100)、61.8%(55/89)、61.9%(39/63)。
- 溃疡性结肠炎内镜缓解在3、6、12个月分别为27.5%(11/40)、41.0%(16/39)、47.8%(22/46)。
- 多变量分析中,与克罗恩病相比,溃疡性结肠炎患者以及病情较轻者更可能在6个月和12个月均达到客观定义的缓解。
关键数值与推荐
- 临床缓解定义为完全、无激素的症状消失。
- 客观缓解定义为内镜下黏膜愈合或对比增强超声或CT/MR小肠造影影像学表现正常化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vedolizumab is an α4β7 integrin antagonist with proven efficacy for inducing and maintaining clinical response and remission in Crohn's disease (CD) and ulcerative colitis (UC). AIM: To evaluate clinical and objective response and remission rates with vedolizumab in a large, real world cohort. METHODS: A retrospective cohort study of adult CD and UC patients receiving vedolizumab between 2012 and 2017 was conducted. PRIMARY OUTCOME: clinical or objective response and remission at 3, 6 and 12 months after induction. Clinical remission was defined by complete, steroid-free absence of symptoms. Objective remission was defined by endoscopic mucosal healing or normalisation of radiographic appearance on contrast-enhanced ultrasound or CT/MR enterography. RESULTS: The study included 222 vedolizumab patients (122 CD, 100 UC). In CD, clinical remission at 3, 6 and 12 months was achieved in 19.8% (22/111), 22.1% (21/95) and 22.1% (15/68) of patients, respectively. Objective remission occurred in 11.5% (6/52), 21.2% (14/66), and 18.9% (7/37) of patients at 3, 6 and 12 months, respectively. In UC, clinical remission at 3, 6, and 12 months was 51.0% (51/100), 61.8% (55/89) and 61.9% (39/63), respectively. Endoscopic remission occurred in 27.5% (11/40), 41.0% (16/39) and 47.8% (22/46) of patients at 3, 6 and 12 months, respectively. In multivariable analysis, patients with UC as compared to CD, and those with milder disease activity were more likely to achieve objectively defined remission at both 6 and 12 months. CONCLUSIONS: Vedolizumab was effective for induction and maintenance of clinical and objective remission, both in Crohn's disease and ulcerative colitis.
引用
- Kotze PG, Ma C, Almutairdi A, et al. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2018. PMID: 30063077. doi:10.1111/apt.14919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。